PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have entered the clinics for their promising anticancer effect as adjuvant in chemo- and radiotherapy and as single agent on BRCA-mutated tumours. Poly(ADP-ribose) glycohydrolase (PARG) deficiency was also shown to potentiate the cytotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Noll, Aurélia, Illuzzi, Giuditta, Amé, Jean-Christophe, Dantzer, Françoise, Schreiber, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929728/
https://www.ncbi.nlm.nih.gov/pubmed/27375368
http://dx.doi.org/10.1186/s12935-016-0333-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929728/
https://www.ncbi.nlm.nih.gov/pubmed/27375368
http://dx.doi.org/10.1186/s12935-016-0333-2

Ejemplares similares